Sep 12, 2023 / 04:15PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Great. Well, good afternoon, everybody. Thanks for joining us. I'm Terence Flynn, the U.S. biopharma analyst at Morgan Stanley. We're very pleased to be hosting Moderna this afternoon. We have Stephane Bancel, who is the company's CEO. Stephane, thanks so much for being here.
Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Stephane, thanks so much again for your time today. Really looking forward to catching up again as it's been a while, as we were just talking about before.
Questions and Answers:
Terence C. Flynn - Morgan Stanley, Research Division - Equity AnalystMaybe I thought the place to start, just high level, give us an update on kind of strategic focus for the company here and capital allocation priorities as obviously, we're shifting to this kind of post-pandemic world here
Trustpilot
